Top Abstract Purchase Related
Home
>
Node
>
Subnode

Comparison of the Effectiveness of Low-Dose Indinavir/Ritonavir (IDV/r) - versus Atazanavir/Ritonavir (ATV/r) -Based Generic Antiretroviral Therapy in NNRTI-Experienced HIV-1-Infected Patients in India

Patel, A.K.; Patel, K.K.; Naik, E.; Jingyi Duan; Ranjan, R.; Patel, J.K.; Salihu, H.M.

Journal of the International Association of Physicians in Aids Care 10(2): 111-118

2011

ISSN/ISBN: 1557-0886
PMID: 21317161
DOI: 10.1177/1545109710385121
Document Number: 558033
Currently, data on the effectiveness of second-line antiretroviral regimens using indinavir/ritonavir (IDV/r) and atazanavir/ritonavir (ATV/r) along with 2 nucleoside reverse transcriptase inhibitor (NRTI) in resource-poor settings is limited. Observational follow-up study on 441 patients who experienced treatment failure to first-line nonnucleoside reverse transcriptase inhibitor (NNRTI)-based treatment. Multivariate Cox Proportional Hazards Model was used to assess comparative effectiveness of treatment regimens. A total of 63 patients (14.8%) had failed second line treatments, of which 53 patients (17.2%) were using IDV/r while 10 patients (8.5%) were on ATV/r. After adjusting for age, weight, gender, and baseline CD4 count, patients who took IDV/r were more than twice as likely to experience treatment failure as compared to those who were on ATV/r (hazard ratio [HR] 2.18; 95% confidence interval [CI] 1.14, 4.15). Successful response to second-line therapy was not different between the 2 treatment groups when patients weighed less than 55 kg at baseline (log rank P value = 1.00) in contrast to the individuals weighing ≥55 kg (P < .0001). We found that successful response to second-line therapy was twice as likely in the ATV/r group; however, this difference was eliminated in patients less than 55 kg.

Document emailed within 0-6 h
Secure & encrypted payments

Waters, L.J.; Moyle, G.; Bonora, S.; D'Avolio, A.; Else, L.; Mandalia, S.; Pozniak, A.; Nelson, M.; Gazzard, B.; Back, D.; Boffito, M. 2007: Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients Antiviral Therapy 12(5): 825-830
Piketty, C.; Gérard, L.; Chazallon, C.; Marcelin, A.-G.èv.; Clavel, F.ço.; Taburet, A.-M.; Calvez, V.; Madelaine-Chambrin, I.; Molina, J.-M.; Aboulker, J.-P.; Girard, P.-M. 2006: Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial Antiviral Therapy 11(2): 213-221
Koudriakova, T.; Iatsimirskaia, E.; Utkin, I.; Gangl, E.; Vouros, P.; Storozhuk, E.; Orza, D.; Marinina, J.; Gerber, N. 1998: Metabolism of the human immunodeficiency virus protease inhibitors indinavir and ritonavir by human intestinal microsomes and expressed cytochrome P4503A4/3A5: mechanism-based inactivation of cytochrome P4503A by ritonavir Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(6): 552-561
Wasmuth, J.-C.; la Porte, C.J.L.; Schneider, K.; Burger, D.M.; Rockstroh, J.K. 2004: Comparison of two reduced-dose regimens of indinavir (600 mg vs 400 mg twice daily) and ritonavir (100 mg twice daily) in healthy volunteers (COREDIR) Antiviral Therapy 9(2): 213-220
Soria, A.; Gianotti, N.; Cernuschi, M.; Lazzarin, A. 2004: Once-daily saquinavir and ritonavir in treatment-experienced HIV-1-infected individuals New Microbiologica 27(1): 11-15
DuBois, B.N.; Atrio, J.; Stanczyk, F.Z.; Cherala, G. 2015: Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy Contraception 91(1): 71-75
Sherman, K.E.; Shire, N.J.; Cernohous, P.; Rouster, S.D.; Omachi, J.H.; Brun, S.; Da Silva, B. 2005: Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients : Lopinavir-ritonavir versus nelfinavir Clinical Infectious Diseases 41(8): 1186-1195
Disdier, O.M.; Pérez, C.M.; Suárez, E. 1999: A comparative study of indinavir versus ritonavir for assessing the development of opportunistic diseases in adult AIDS patients Boletin de la Asociacion Medica de Puerto Rico 91(7-12): 85-90
Simpson, K.N.; Baran, R.W.; Kirbach, S.E.; Dietz, B. 2011: Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research 14(8): 1048-1054
Pujari, S.; Dravid, A.; Gupte, N.; Joshi, K.; Bele, V. 2008: Effectiveness and safety of generic fixed-dose combination of tenofovir/emtricitabine/efavirenz in HIV-1-infected patients in Western India Medscape Journal of Medicine 10(8): 196
Hsu, A.; Granneman, G.R.; Cao, G.; Carothers, L.; Japour, A.; El-Shourbagy, T.; Dennis, S.; Berg, J.; Erdman, K.; Leonard, J.M.; Sun, E. 1998: Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers Antimicrobial Agents and ChemoTherapy 42(11): 2784-2791
Marcelin, A.-G.; Flandre, P.; de Mendoza, C.; Roquebert, B.; Peytavin, G.; Valer, L.; Wirden, M.; Abbas, S.; Katlama, C.; Soriano, V.; Calvez, V. 2007: Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients Antiviral Therapy 12(2): 247-252
Chong, K.T.; Pagano, P.J. 1997: In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and -resistant clinical isolates Antimicrobial Agents and ChemoTherapy 41(11): 2367-2373
Gianotti, N.; Poli, A.; Galli, M.; Pan, A.; Rizzardini, G.; Soria, A.; Viale, P.; Di Biagio, A.; Quirino, T.; Viganò, P.; Bonfanti, P.; d'Arminio Monforte, A.; Fortino, I.; Lazzarin, A. 2014: Monotherapy with lopinavir/ritonavir versus standard of care in HIV-infected patients virologically suppressed while on treatment with protease inhibitor-based regimens: results from the MoLo study New Microbiologica 37(4): 439-448
Colombo, S.; Buclin, T.; Franc, C.; Guignard, N.; Khonkarly, M.; Tarr, P.E.; Rochat, B.; Biollaz, J.ér.ôm.; Telenti, A.; Decosterd, L.A.; Cavassini, M. 2006: Ritonavir-boosted atazanavir-lopinavir combination: a pharmacokinetic interaction study of total, unbound plasma and cellular exposures Antiviral Therapy 11(1): 53-62
Manosuthi, W.; Sungkanuparph, S.; Ruxrungtham, K.; Prasithsirikul, W.; Athichathanabadi, C.; Tantisiriwat, W.; Bowonwatanuwong, C.; Chumpathat, N.; Chaovavanich, A. 2008: Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir Journal of Acquired Immune Deficiency Syndromes 47(1): 127-129
Galegov, G.A. 2007: Protease inhibitor Kaletra (Lopinavir/Ritonavir): significance and role in antiretroviral therapy of HIV infection and AIDS Antibiotiki i Khimioterapiia 52(1-2): 42-45
Sunpath, H.; Winternheimer, P.; Cohen, S.; Tennant, I.; Chelin, N.; Gandhi, R.T.; Murphy, R.A. 2014: Double-dose lopinavir-ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa International Journal of Tuberculosis and Lung Disease: the Official Journal of the International Union Against Tuberculosis and Lung Disease 18(6): 689-693
Kuschak, D.; Mauss, S.; Schmutz, G.; Gantke, B. 2001: Simultaneous Determination of the New HIV Protease Inhibitor Lopinavir (ABT 378) and of Indinavir (1), Amprenavir, Saquinavir, Ritonavir (ABT 538) (2) and Nelfinavir (3) in Human Plasma by Gradient HPLC Clinical Laboratory 47(9-10): 471-477
Vieira, C.S.; Bahamondes, M.V.; de Souza, R.M.; Brito, M.B.; Rocha Prandini, T.R.; Amaral, E.; Bahamondes, L.; Duarte, G.; Quintana, S.M.; Scaranari, C.; Ferriani, R.A. 2014: Effect of antiretroviral therapy including lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women Journal of Acquired Immune Deficiency Syndromes 66(4): 378-385